| Time | Presentation Title | Speaker | |
|---|---|---|---|
| Tuesday 19 September | |||
| 12pm | Registration & One-to-One Partnering Opens |  | |
| 1pm | NETWORKING LUNCH | ||
| 2pm | Welcome & Introduction | ||
| 2.15pm | Leading biotech companies in the Benelux: Genmab story | Martine van Vugt - Executive Vice President & Chief Strategy Officer, Genmab |  |
| 2.45pm | VC panel discussion: challenges with fundraising in the Biotech sector | Moderator: Eline van Beest - CEO, Hybridize Therapeutics Wouter Joustra - General Partner, Forbion Cillian King - Managing Director, Life Sciences Team, EQT Stefan Luzi - Partner, Gilde Healthcare | |
| 4pm | BREAK | ||
| 4.30pm | New rising star in the Benelux: Agomab | Tim Knotnerus - CEO, Agomab Therapeutics | |
| 5pm | Dual track exit strategies - M&A v IPOs in 2023: a banking perspective | Nadine Maalouf - Managing Director Life Sciences & Healthcare, Corporate Finance, Van Lanschot Kempen | |
| 5.30pm | Networking drinks reception Midtown Grill Restaurant, Marriott Amsterdam | ||
| 8pm | FINISH | ||
| Wednesday 20 September | |||
| 8.30am | One-to-One Partnering Opens | | |
| 9.30am | Welcome | ||
| 9.35am | Keynote address | Jim Joyce - CEO & Co-Founder, HealthBeacon | |
| 10.15am | Panel discussion: M&A landscape in 2023 | Moderator: Paul van der Horst - Chief Business Officer, Agomab Therapeutics David Flint - Head of M&A, UCB Nathalie ter Wengel - European Lead Worldwide Business Development, Pfizer Chris Vaes - Senior Director BD, J&J | |
| 11am | Going up North - a glimpse on the Nordic biotech landscape | Stephan Christgau - Founding Partner, Eir Ventures | |
| 11.30am | BREAK | ||
| 12pm | Panel discussion: challenging biotech stories | Moderator: Jan De Kerpel - Head of Life Sciences & Healthcare, Van Lanschot Kempen René Beukema - Chief Corporate Development Officer & General Counsel, ProQR Therapeutics N.V. Richard Porter - CBO, uniQure Erik van den Berg - Non-Executive Board Member & Strategic Advisor, AM-Pharma | |
| 1pm | LUNCH | ||
| Pitch & Partner Session 1 | |||
| 2pm 2.15pm 2.30pm 2.45pm 3pm | Aspire Pharma Tillotts BioRep Intsel Chimos Allergy Therapeutics | ||
| 3.15pm | BREAK | ||
| 3.45pm | Digital health landscape | Jan Vandenneucker - Neurology Digital Strategy & Project Lead, UCB | |
| 4.30pm | Deal certainty & key success factors for dealmakers | Hayfa Konrad - Legal Counsel | |
| 4.55pm | Panel discussion: Deal making success blueprint - putting it all together | Moderator: Hans Schikan - Chairman of the Board, Microbiotica, former special envoy for vaccines Juergen Heitmann - Senior Director Business Development & Alliance Management, Shionogi Markus Werner - Head Search & Evaluation Oncology, Novartis Ragip Ziyal - Head of Corporate Development, Tillotts Pharma | |
| 5.45pm | Close | ||
| 6pm | Meet at conference registration desk | ||
| 6.15pm | Boat transfer through Amsterdam canals | ||
| 6.45pm | Arrive at De Koepelkerk | ||
| 7.45pm | Dinner at De Koepelkerk | ||
| Thursday 21 September | |||
| 8.30am | One-to-One Partnering Opens | | |
| Pitch & Partner session 2 | |||
| 9.30am 9.45am 10am 10.30am | Luye Pharma International Health Partners IPLS Nucleo | ||
| 11am | BREAK | ||
| 11.30am | Digital health landscape: MedTech | Erik de Heus - CEO, Skin Vision | |
| 12pm | Digital health: DTx | Francesca Wuttke, CEO and Founder, nen | |
| 12.30pm | Digital health: Clinical Trials | ||
| 1pm | Digital health: Panel discussion | ||
| 1.30pm | LUNCH | ||
| 2.30pm | CLOSE | ||
Follow us on LinkedIn to keep up to date
